New pill tested for Tough-to-Treat bile duct cancer in japan
NCT ID NCT06081829
Summary
This study is testing a daily oral medication called ivosidenib for Japanese patients with advanced bile duct cancer that has a specific genetic change (IDH1 mutation) and has worsened after one or two prior treatments. The main goal is to see if the treatment can keep the cancer from growing for at least six months. Researchers will also monitor how patients feel, side effects, and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hokkaido University Hospital (JPN-006)
Sapporo, 060-8648, Japan
-
Kanagawa Cancer Center (JPN-003)
Yokohama, 241-8515, Japan
-
Kumamoto University Hospital (JPN-004)
Kumamoto, 860-8556, Japan
-
National Cancer Center Hospital (JPN-001)
Tokyo, Japan
-
National Cancer Center Hospital East (JPN-002)
Kashiwa, 277-8577, Japan
-
National Hospital Organization Shikoku Cancer Center (JPN-007)
Matsuyama, 791-0280, Japan
-
Osaka International Cancer Institute (JPN-005)
Osaka, 541-8567, Japan
Conditions
Explore the condition pages connected to this study.